Compare J B Hunt Transport Services Inc (JBHT) vs Novo Nordisk A/S (NVO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
J B Hunt Transport Services Inc vs Novo Nordisk A/S — how do they compare? J B Hunt Transport Services Inc trades at $291.15 (market cap $27.36B), while Novo Nordisk A/S trades at $49.61 (market cap $220.53B). The key difference: Novo Nordisk A/S is far larger — about 8.1× J B Hunt Transport Services Inc's market cap, and Novo Nordisk A/S pays the higher dividend (3.63%). Which is the better fit depends on your goals.
| JBHT | NVO | |
|---|---|---|
Market Cap | $27.36B | $220.53B |
Sector | Industrials | Health |
52-Week High | $298.41 | $71.70 |
52-Week Low | $130.65 | $35.29 |
Enterprise Value | $28.50B | $239.49B |
Dividend Yield | 0.62% | 3.63% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
JBHT trades at $290.43, down 0.34% today but near its 52-week high, with a bullish technical outlook and consistent earnings beats. The stock shows strong momentum, supported by intermodal growth and cost discipline. Recent Q2 2026 EPS of $1.91 beat estimates by 12%, driving positive sentiment. Valuation remains elevated with a P/E of 41.45, reflecting high growth expectations amid industry capacity constraints.
Outlook is positive due to structural freight market shifts and operational efficiency, but risks include premium valuation sensitivity and economic cyclicality. Analyst consensus favors Buy with a $299.82 target, suggesting modest upside. Investors should weigh robust fundamentals against potential margin pressures from rising costs.
Novo Nordisk (NVO) trades at $49.68, down 1.27% on the day, amid a bullish technical signal from moving averages. The company demonstrates robust fundamentals with a trailing P/E of 12.08 and a net income margin of 37.2%, supported by three consecutive quarterly earnings beats. Recent positive catalysts include EU and Indian regulatory approvals for its oral Wegovy weight-loss pill, expanding its GLP-1 franchise.
The outlook remains positive given strong analyst consensus (57.9% Buy ratings) and projected earnings growth, though risks include intensifying competition in the weight-loss drug market and potential margin pressure. The stock presents a compelling opportunity for investors seeking exposure to a profitable leader in metabolic diseases.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About J B Hunt Transport Services Inc
J.B. Hunt Transport Services ranks among the top surface transportation companies in North America by revenue. Its primary operating segments are intermodal delivery, which uses the Class I rail carriers for the underlying line-haul movement of its owned containers (45% of sales in 2021).
Read more on JBHT →About Novo Nordisk A/S
With almost 50% market share by volume of the global insulin market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments, and oral antidiabetic agents. Novo also has a biopharmaceutical segment (constituting roughly 15% of revenue) that specializes in protein therapies for hemophilia and other disorders.
Read more on NVO →
